Illumina has held a virtual monopoly over high throughput sequencing over the past 15 years, basically cancelling what many expected to be a drastic decrease in

Illumina has held a virtual monopoly over high throughput sequencing over the past 15 years, basically cancelling what many expected to be a drastic decrease in the cost of DNA sequencing. Now a company called Stratos (acquired by Roche in 2020), has developed a new sequencing technology that claims to be better, more accurate, and cheaper